Menu
en
fr
nl
About Us
Bone Therapeutics in brief
Mission
History
Management
Board of Directors
Scientific Advisory Board
Team
Technology
Unique technology platform
Intellectual property
Products
Pipeline
PREOB
®
ALLOB
®
Indications
Clinical studies
General information
Ongoing studies
Investigator interviews
Participation
Partnering
Our Partners
Licensing Opportunities
Investors
Share Price
Shareholder Information
Financial Calendar
Financial Information
Regulated Information
Governance
Shareholders Meeting
Presentations
Events
IR Contact
Careers
Job Opportunities
Spontaneous Applications
News & Events
Press Releases
Media Coverage
News
Upcoming Events
Newsletter Subscription
10 Years
Contact
Contact
if you are a robot type something
Home
News & Events
Press Releases
Press releases
2017
2016
2015
2014
2013
2012
2011
2010
July
7/3/17 - Bone Therapeutics strengthens board of directors
June
6/26/17 - Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform
6/8/17 - Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB
May
5/29/17 - Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors
5/11/17 - Bone Therapeutics Business Update for First Quarter 2017
April
4/26/17 - Bone Therapeutics: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available
4/25/17 - Bone Therapeutics announces the publication of its Annual Report 2016
March
3/16/17 - Bone Therapeutics Reports Full Year 2016 Results
3/10/17 - Bone Therapeutics to participate in upcoming key investor conferences
3/9/17 - Bone Therapeutics completes recruitment of 16 patients in ALLOB Phase I/IIA delayed-union study
3/6/17 - Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer
3/3/17 - Bone Therapeutics Notice of Full Year 2016 Results
January
1/20/17 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2017
1/17/17 - Bone Therapeutics Provides Business Update for Q4 2016
1/6/17 - Bone Therapeutics Granted EUR 2.3 Million in Non-Dilutive Funding by the Walloon Region
December
12/21/16 - Bone Therapeutics announces its financial calendar for 2017
November
11/8/16 - Bone Therapeutics Business Update for Third Quarter 2016
11/2/16 - Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016
October
10/11/16 - Enrico Bastianelli to stand down as CEO of Bone Therapeutics
10/11/16 - Transparency notification received from Theodorus II SA
10/5/16 - Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial
September
9/15/16 - Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction
August
8/30/16 - Bone Therapeutics announces H1 results for 2016
8/25/16 - Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016
June
6/8/16 - Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
6/3/16 - Bone Therapeutics celebrates ten years of innovation in bone cell therapy
May
5/19/16 - Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
5/17/16 - Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
5/10/16 - Bone Therapeutics Provides Business Update for the First Quarter of 2016
5/3/16 - Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study
April
4/26/16 - The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available
4/14/16 - Bone Therapeutics announces the publication of its Annual Report 2015
March
3/29/16 - Bone Therapeutics Reports Full Year 2015 Results
3/29/16 - Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
3/16/16 - Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016
February
2/24/16 - Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference
2/17/16 - Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015
2/17/16 - Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
2/2/16 - Bone Therapeutics extends Kasios collaboration
January
1/20/16 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016
1/18/16 - Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures
1/13/16 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016
1/5/16 - Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region
December
12/23/15 - Bone Therapeutics announces its financial calendar for 2016
12/15/15 - Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial
12/11/15 - ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference
November
11/30/15 - Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
11/18/15 - Bone Therapeutics Provides Business Update for the Third Quarter of 2015
11/12/15 - Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA
11/9/15 - Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer
October
10/22/15 - Transparency notification received from S.R.I.W. SA & Sofipôle SA
10/13/15 - Bone Therapeutics to participate in key investor conferences in Q4 2015
September
9/28/15 - Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion
9/22/15 - Bone Therapeutics announces half-year results for 2015
9/21/15 - Bone Therapeutics Notice of Half Year Results 2015
9/7/15 - Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial
June
6/22/15 - Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis
May
5/15/15 - Bone Therapeutics Provides Business Update for the First Quarter 2015
April
4/28/15 - Bone Therapeutics Reports 2014 Financial and Operational Results
4/24/15 - Bone Therapeutics officially opens its new headquarters in Gosselies
4/13/15 - Bone Therapeutics Establishes US Subsidiary
March
3/23/15 - Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial
3/2/15 - Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial
February
2/19/15 - Information on the total number of voting rights and shares
2/18/15 - Bone Therapeutics announces its financial calendar for 2015
2/17/15 - Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA
2/16/15 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015
2/11/15 - Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
2/4/15 - Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris
January
1/21/15 - Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris
1/19/15 - Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
1/16/15 - Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
1/5/15 - Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product
December
12/4/14 - Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®
November
ALLOBIF Collaboration
11/17/14 - Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures
October
Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany
September
Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)
July
Bone Therapeutics and Partners awarded over €0.5 million M-ERA.net research funding to develop 3-D patient-tailored bone tissue engineered products
June
Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product
January
Bone Therapeutics to present at Biotech Showcase in San Francisco on Tuesday 14 January, 2014 at 10.15am
December
Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant
November
Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active
Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures
October
Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial
September
Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer
June
Establishment of the Walloon Cell Therapy Platform: The platform aims to produce cell therapy medicines on a large scale
Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle
April
Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®
Bone Therapeutics to Present at Upcoming Investor Conferences
March
Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products
February
Bone Therapeutics Invests in Cell Therapy Manufacturing Facility
January
Bone Therapeutics Raises €7.7 Million in Series D Fundraising
October
Bone Therapeutics receives clearance for its pivotal phase III osteonecrosis trial with PREOB® in Europe and treats the first patients in the study
Bone Therapeutics reçoit l'approbation des autorités et traite les premiers patients dans son étude clinique de phase III en ostéonécrose avec son produit PREOB®
February
Bone Therapeutics lève 9,5M €
June
Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel
